Join us at the Swiss Biotech Day – April 22-23
The 2024 edition of Swiss Biotech Day will begin on the 23rd of April in Basel, Switzerland and of course, Orion Biotechnology will be there. We hope to see you
Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
Orion Biotechnology is discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapies to treat metabolic and immunological diseases
Orion’s novel drug modality involves precision engineering ligands of small protein GPCRs, providing an enhanced solution to targeting previously-undrugged GPCRs. This approach is supported by one of the fastest drug discovery platforms in the industry and represents a large opportunity to discover and develop a new generation of GPCR-targeted medicines
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Infectious Disease and Neuroinflammatory disorders.
Recognized
Leadership
Previous slide
Next slide
Presenting at BioPharma Drug Discovery Nexus – Apr 25-26
Join Nicolas Calo (Senior Scientist at Orion Biotechnology), at the 19th Biopharma Drug Discovery Nexus being held in Basel, Switzerland. Nicolas will showcase Orion’s PROcisionXTM platform and its ability to
Orion Biotechnology Presented at the 3rd GPCR-Targeted Drug Discovery Summit in Boston
March 13, 2024
Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
Orion Biotechnology featured on BestStock.com
August 29, 2023
You can find the investment blog – BestStocks.com – and their take on the potential of Orion’s technology in a recently published article here.
Orion Biotechnology Completes Discovery of First-in-Class Molecule Against Undrugged GPCR Target in Four Months
July 18, 2023
Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
